



sanofi pasteur exercises option on Intercell's bacterial vaccine antigens - up to EUR 23 m license and milestone payments

Vienna - July 1, 2005 – Intercell AG (VSE - "ICLL") today announced that its partner sanofi pasteur S.A. (previously aventis pasteur S.A.), the vaccines business of the sanofi-aventis group, exercised its option on exclusive worldwide commercial rights on certain bacterial vaccine antigens, which have been identified by Intercell's Antigen Identification Program under a Collaboration and License Option Agreement the parties concluded in December 2003.

The option exercise will trigger license fees and recognition of previously unearned research funding and success fees resulting in an aggregate value of about € 3 million. Over the entire term of the agreement Intercell will be entitled to further milestone based license payments totaling to about € 20 million, as well as royalties on future net sales.

"Our partner sanofi pasteur is a leader and innovator in the field of vaccines and we are delighted that our Antigen Identification Program has again successfully delivered attractive vaccine antigens for another important bacterial indication with a high unaddressed medical need," states Intercell's Chief Operating Officer, Gerd Zettlmeissl.

"Intercell's Antigen Identification Program is a very promising new technology for the field of vaccine development", commented Michel DeWilde, Executive Vice-president, Research and Development at sanofi pasteur. "We are impressed with the excellent progress Intercell has made in this important project."

About Intercell AG

Intercell AG is a fast growing biotechnology company focusing on the design and development of novel vaccines for prevention and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis about to enter Phase III, a vaccine for Hepatitis C undergoing Phase II trials, and five products focused on infectious diseases in the pre-clinical phase. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com





Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained herein is not for publication or distribution in the United States of America. This press release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from Intercell AG and that will contain detailed information about the company and management, as well as financial statements.